ABBV-706 Yields Durable Responses and Is Deemed Tolerable in R/R SCLC – OncLive
- ABBV-706 Yields Durable Responses and Is Deemed Tolerable in R/R SCLC OncLive
- WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer MD Anderson Cancer Center
- Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug BIOENGINEER.ORG
- Antibody drug shows promise against lung cancer in first human trial AP7AM
Discover more from News Hub
Subscribe to get the latest posts sent to your email.
